[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 35 of about 35
1. Holsinger FC, Lin HY, Bassot V, Laccourreye O: Platin-based exclusive chemotherapy for selected patients with squamous cell carcinoma of the larynx and pharynx. Cancer; 2009 Sep 1;115(17):3909-18
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Platin-based exclusive chemotherapy for selected patients with squamous cell carcinoma of the larynx and pharynx.
  • BACKGROUND: The current study was conducted to determine the long-term outcomes of patients with squamous cell carcinoma of the larynx and pharynx who were treated with platin-based exclusive chemotherapy (EC) after they achieved a complete clinical response (CCR) to induction chemotherapy.
  • METHODS: One hundred forty-two who achieved a CCR after platin-based induction chemotherapy were treated exclusively with additional chemotherapy, and 98.6% were followed for a minimum of 3 years or until death.
  • In multivariate analysis, primary tumor arising outside the glottic larynx (P = .0001) and a Charlson comorbidity index >1 (P = .0001) were associated with a statistically significant reduction in survival.
  • Salvage treatment resulted in an observed final local control rate of 93% that varied from 97.2% in patients who had glottic cancer to 88.7% in patients who had tumor originating from other sites (P = .097).
  • Combined chemotherapy with cisplatin and 5-fluorouracil (PF) allowed for the successful modulation of local therapy in 54.9% of patients.
  • For patients who developed recurrent disease after EC, this approach did not diminish survival and maintained function in the majority of patients.
  • Future work should be directed toward select markers of response to PF chemotherapy with which to identify those patients who are suited optimally for this approach.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1983 Apr 15;51(8):1353-5 [6681726.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):327-33 [12525526.001]
  • [Cites] Head Neck Surg. 1983 Jul-Aug;5(6):500-7 [6885503.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] Cancer. 1987 Sep 15;60(6):1178-83 [3304610.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] J Natl Cancer Inst. 1994 Feb 16;86(4):265-72 [8158680.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):83-91 [7819055.001]
  • [Cites] Head Neck. 1995 Sep-Oct;17(5):377-81 [8522437.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):838-47 [8622032.001]
  • [Cites] J Natl Cancer Inst. 1996 Jul 3;88(13):890-9 [8656441.001]
  • [Cites] J Clin Oncol. 1996 Aug;14(8):2331-6 [8708725.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] Lancet Oncol. 2006 Jul;7(7):565-74 [16814208.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):570-80 [16899777.001]
  • [Cites] J Laryngol Otol. 2007 Feb;121(2):143-8 [17005065.001]
  • [Cites] N Engl J Med. 2008 Sep 11;359(11):1143-54 [18784104.001]
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] Laryngoscope. 2000 Jan;110(1):58-64 [10646717.001]
  • [Cites] Head Neck. 2004 Apr;26(4):365-72 [15054740.001]
  • [Cites] Br J Cancer. 2000 Dec;83(12):1594-8 [11189100.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1504-11 [11745228.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • (PMID = 19551883.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K12 CA88084; United States / NCI NIH HHS / CA / K12 CA088084-09; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P50 CA097007; United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / K12 CA088084; United States / NCI NIH HHS / CA / P50 CA97007
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Platinum Compounds; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ NIHMS124415; NLM/ PMC3851301
  •  go-up   go-down


2. Ishihara S, Kubota S, Itoh J, Fujimoto Y, Nakashima T, Naganawa S: Radiotherapy with or without chemotherapy for patients with T1-T2 glottic carcinoma: retrospective analysis. Head Neck Oncol; 2010 Jul 30;2:20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy with or without chemotherapy for patients with T1-T2 glottic carcinoma: retrospective analysis.
  • BACKGROUND: To assess the results for local control (LC) and survival in patients with early-stage glottic cancer (GC) who were treated by radiotherapy (RT) with or without chemotherapy.
  • METHODS: Fifty-eight patients with T1-T2 squamous cell carcinoma of the glottis who were treated between 2001 and 2006 were analyzed retrospectively.
  • Of the 58 patients, eight developed recurrent disease at the primary site, and one had lymph node recurrences on the neck.
  • Only two patients died of laryngeal carcinoma, and one died of intercurrent disease.
  • CONCLUSIONS: The retrospective analysis showed a high rate of LC and larynx preservation in patients with T1-T2 GC by means of RT with or without chemotherapy.
  • There was, however, no statistical difference in LC rates for the two types of therapy.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Glottis / pathology. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):21-6 [10656367.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1104-9 [18950960.001]
  • [Cites] J Clin Oncol. 2001 Oct 15;19(20):4029-36 [11600604.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):109-19 [11777628.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):415-9 [11872287.001]
  • [Cites] Head Neck. 2002 Jul;24(7):637-42 [12112536.001]
  • [Cites] Int J Cancer. 2002 Aug 1;100(4):472-5 [12115532.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):471-8 [12243824.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Feb 1;55(2):322-8 [12527044.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):765-72 [12910521.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 Mar;13(3):313-7 [3104243.001]
  • [Cites] Radiother Oncol. 1998 May;47(2):161-6 [9683364.001]
  • [Cites] Laryngoscope. 1998 Dec;108(12):1853-5 [9851503.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1378-86 [16095847.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1387-94 [16115737.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):77-82 [16169681.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):995-1001 [16406396.001]
  • [Cites] J Clin Oncol. 2006 Aug 1;24(22):3693-704 [16832122.001]
  • [Cites] Radiat Med. 2006 May;24(4):277-81 [16958401.001]
  • [Cites] Oncology. 2006;71(5-6):369-73 [17851262.001]
  • [Cites] Anticancer Res. 2007 Sep-Oct;27(5B):3497-500 [17972507.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Dec 1;69(5):1389-94 [17869013.001]
  • [Cites] Auris Nasus Larynx. 2008 Jun;35(2):213-9 [17996416.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):723-35 [11020569.001]
  • (PMID = 20673360.001).
  • [ISSN] 1758-3284
  • [Journal-full-title] Head & neck oncology
  • [ISO-abbreviation] Head Neck Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2919535
  •  go-up   go-down


3. Galetta D, Giotta F, Rosati G, Gebbia V, Manzione L, Di Bisceglie M, Borsellino N, Colucci G: Carboplatin in combination with raltitrexed in recurrent and metastatic head and neck squamous cell carcinoma: A multicentre phase II study of the Gruppo Oncologico Dell'Italia Meridionale (G.O.I.M.). Anticancer Res; 2005 Nov-Dec;25(6C):4445-9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carboplatin in combination with raltitrexed in recurrent and metastatic head and neck squamous cell carcinoma: A multicentre phase II study of the Gruppo Oncologico Dell'Italia Meridionale (G.O.I.M.).
  • BACKGROUND: The combination of cisplatin (CDDP) and 5-Fluorouracil (5-FU) is a standard regimen for the treatment of recurrent and metastatic head and neck squamous cell carcinoma (HNSCC).
  • This combination shows a relevant toxicity and new chemotherapy associations with a more favourable toxicity profile are awaited.
  • MATERIALS AND METHODS: Since 2001, a multicentre, phase II trial has been underway to evaluate the efficacy and toxicity of the CB+R combination in untreated patients with recurrent or metastatic HNSCC.
  • Patients had a histo/cytologically proven recurrent or metastatic HNSCC; patients with locally advanced disease not amenable to CDDP+5-FU treatment were also included.
  • Twelve patients were staged III and 20 were metastatic (10 recurrent).
  • The oral cavity/oropharynx were the primary site in 20 patients and the larynx in 10 patients.
  • The median time to progression was 4.2 months and median duration of survival was 9.8 months.
  • Eight patients (25%) had a G 3-4 neutropenia, while G 3-4 anaemia was observed in 2 patients and thrombocytopenia in 1 patient.
  • CONCLUSION: In our phase II trial, CB in combination with R showed a moderate activity with safe administration on an outpatient basis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334124.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Quinazolines; 0 / Thiophenes; BG3F62OND5 / Carboplatin; FCB9EGG971 / raltitrexed
  •  go-up   go-down


Advertisement
4. Sher DJ, Haddad RI, Norris CM Jr, Posner MR, Wirth LJ, Goguen LA, Annino D, Balboni T, Allen A, Tishler RB: Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer. Cancer; 2010 Oct 15;116(20):4761-8
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer.
  • BACKGROUND: Patients with locally recurrent squamous cell cancer of the head and neck (SCCHN) are reported to have a poor prognosis and limited therapeutic options.
  • This study reported the experience of the Dana-Farber Cancer Institute (DFCI) with IMRT-based chemoradiotherapy with or without surgery for locally recurrent SCCHN.
  • METHODS: The current study was a retrospective study of all patients treated at DFCI who were diagnosed with nonmetastatic second primary or recurrent SCCHN and who received reirradiation based on IMRT.
  • Recurrent disease was treated in the oral cavity (4 patients), larynx/hypopharynx (13 patients), oropharynx (7 patients), nasopharynx (2 patients), and neck (9 patients).
  • The median radiation dose was 60 Gray (Gy), and all patients received concurrent chemotherapy.
  • Approximately 91% and 46%, respectively, of all patients developed at least 1 acute and late grade 3 toxicity.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / radiotherapy. Neoplasms, Second Primary / radiotherapy. Radiotherapy, Intensity-Modulated
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / radiotherapy. Retreatment. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Cancer Society.
  • (PMID = 20572036.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Choong N, Vokes E: Expanding role of the medical oncologist in the management of head and neck cancer. CA Cancer J Clin; 2008 Jan-Feb;58(1):32-53
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The multidisciplinary approach to treating squamous cell carcinoma of the head and neck is complex and evolving.
  • This article aims to review some recent developments in squamous cell carcinoma of the head and neck, in particular the expanding role of chemotherapy in its management.
  • Surgery and radiotherapy have remained the mainstay of therapy.
  • Chemotherapy is increasingly being incorporated into the treatment of squamous cell carcinoma of the head and neck.
  • Previously, radiotherapy following surgery was the standard approach to the treatment of locoregionally advanced resectable disease.
  • Induction chemotherapy has been useful in resectable disease where organ preservation is desirable, but this approach was inferior for the goal of larynx preservation, while leading to similar survival when compared with concomitant chemoradiotherapy.
  • There is recent evidence that taxanes added to induction chemotherapy with cisplatin and fluorouracil result in improved survival outcomes.
  • Novel targeted agents, such as epidermal growth factor receptor antagonists, are showing promise in the treatment of patients with both locoregionally advanced and recurrent/metastatic squamous cell carcinoma of the head and neck.
  • [MeSH-major] Head and Neck Neoplasms / therapy
  • [MeSH-minor] Alcohol Drinking / adverse effects. Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Humans. Neoplasm Metastasis. Neoplasm Recurrence, Local / therapy. Neoplasm Staging. Papillomavirus Infections / complications. Physician's Role. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Risk Factors. Smoking / adverse effects

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18096865.001).
  • [ISSN] 0007-9235
  • [Journal-full-title] CA: a cancer journal for clinicians
  • [ISO-abbreviation] CA Cancer J Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Number-of-references] 206
  •  go-up   go-down


6. Massa E, Dessì M, Gaspardini G, Saba F, Cherchi V, Mantovani G: Phase II study of vinorelbine/cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck progressing after at least two chemotherapy regimens. Oral Oncol; 2010 Nov;46(11):818-21
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of vinorelbine/cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck progressing after at least two chemotherapy regimens.
  • The aim of the present study was to identify a potentially effective new treatment regimen for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck in disease progression after at least two previous chemotherapy regimens.
  • The regimen was administered to patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck previously treated with surgery, radiotherapy or both and progressing after at least two chemotherapy regimens.
  • Twenty-four patients with histologically confirmed tumors of oral cavity, oropharynx, hypopharynx and larynx were enrolled.
  • After 3 cycles of treatment 23 patients (95.8%) were evaluable for response: 4 patients had partial response; 12 stable disease and 7 progressive disease.
  • The present study shows that the combination of Vinorelbine and Cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck patients is effective, feasible and has a good safety profile.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20920877.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 5V9KLZ54CY / Vinblastine; PQX0D8J21J / Cetuximab; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


7. Labourey JL, Cupissol D, Calais G, Tourani JM, Kohser F, Borel C, Eymard JC, Germann N, Tubiana-Mathieu N: Docetaxel plus gemcitabine in recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study. Am J Clin Oncol; 2007 Jun;30(3):278-82
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docetaxel plus gemcitabine in recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study.
  • OBJECTIVES: This phase II study was conducted to assess the efficacy of docetaxel plus gemcitabine in locally recurrent and/or metastatic squamous cell carcinoma of the head and neck.
  • PATIENTS AND METHODS: Forty patients with pharynx or larynx cancer were included and treated with an intravenous infusion of docetaxel 75 mg/m2 on day 8 and gemcitabine 1000 mg/m2 day 1 and day 8 every 3 weeks for 6 cycles.
  • RESULTS: Among the 40 patients included, 17 had metastatic disease and 18 had received prior chemotherapy.
  • Three treatment-related deaths due to infection were reported.
  • CONCLUSION: The docetaxel and gemcitabine combination is an active treatment of recurrent or metastatic head and neck cancer.
  • However, this regimen is associated with a high hematologic toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Humans. Laryngeal Neoplasms / drug therapy. Male. Middle Aged. Pharyngeal Neoplasms / drug therapy. Recurrence. Taxoids / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17551305.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


8. Calais G: [Docetaxel and squamous cell carcinoma of the head and neck]. Bull Cancer; 2004 Feb;91(2):167-71
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Docetaxel and squamous cell carcinoma of the head and neck].
  • [Transliterated title] Docetaxel et carcinomes de la tête et du cou.
  • Chemotherapy in head and neck carcinoma is used as palliative treatment but also as induction treatment or combined treatment with concurrent radiation therapy.
  • Docetaxel is an active drug for treating head and neck carcinoma.
  • For patients with recurrent or metastatic disease, docetaxel could be used either as a second line chemotherapy or a first line for patients who received previously platinum or 5FU.
  • In combination with platinum and 5FU, used as induction chemotherapy the TPF regimen is a very active treatment with an overall response rate of 85 to 90% with a manageable acute toxicity rate.
  • This approach is under investigation in terms of ability to obtain more larynx preservation compared to the standard approach with platinum and 5FU.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Taxoids / therapeutic use
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Fluorouracil / administration & dosage. Humans. Remission Induction

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright John Libbey Eurotext 2003.
  • (PMID = 15047456.001).
  • [ISSN] 0007-4551
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel; U3P01618RT / Fluorouracil
  • [Number-of-references] 21
  •  go-up   go-down


9. Mukherji SK, Weadock WJ: Imaging of the post-treatment larynx. Eur J Radiol; 2002 Nov;44(2):108-19

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging of the post-treatment larynx.
  • The treatment for squamous cell carcinoma of the upper aerodigestive tract includes surgery, radiation therapy (RT), chemotherapy or a combination of various modalities.
  • Familiarization with the expected imaging changes following therapy allow accurate evaluation of imaging studies and may prevent misinterpretation of post-treatment changes as recurrent disease.
  • The intent of this manuscript will be to review the post-treatment appearance of the larynx following RT and various types of laryngectomy.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Laryngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / surgery. Larynx / radiography. Neoplasm Recurrence, Local / radiography
  • [MeSH-minor] Combined Modality Therapy. Diagnosis, Differential. Humans. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12413679.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 17
  •  go-up   go-down


10. Lott DG, Krakovitz PR: Squamous cell carcinoma associated with intralesional injection of cidofovir for recurrent respiratory papillomatosis. Laryngoscope; 2009 Mar;119(3):567-70
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma associated with intralesional injection of cidofovir for recurrent respiratory papillomatosis.
  • Recurrent respiratory papillomatosis is a common neoplasm of the larynx that may lead to severe, recurrent lesions.
  • Intralesional injection of cidofovir has shown promise as an adjuvant therapy.
  • We report a case of invasive squamous cell cancer arising from squamous papilloma in a patient treated with multiple injections of cidofovir.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Carcinoma, Squamous Cell / chemically induced. Cytosine / analogs & derivatives. Neoplasms, Second Primary / chemically induced. Organophosphonates / adverse effects. Papilloma / drug therapy. Tracheal Neoplasms / drug therapy
  • [MeSH-minor] Child. Female. Follow-Up Studies. Humans. Injections, Intralesional / adverse effects. Otorhinolaryngologic Surgical Procedures / methods. Tomography, X-Ray Computed. Trachea / surgery

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Laryngoscope. 2010 Mar;120(3):650; author reply 651 [20013845.001]
  • (PMID = 19235765.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


11. El Bakkouri W, Racy E, Vereecke A, Gauthier A, Quillard J, Bobin S, Portier F: [Squamous cell carcinoma in a thyroglossal duct cyst]. Ann Otolaryngol Chir Cervicofac; 2004 Nov;121(5):303-5
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Squamous cell carcinoma in a thyroglossal duct cyst].
  • [Transliterated title] Carcinome épidermoïde sur kyste du tractus thyréogosse.
  • OBJECTIVE: To present a case of squamous cell carcinoma developed on a thyroglossal duct cyst in an adult patient.
  • Modalities of treatment and prevention are discussed.
  • Surgery was incomplete because of carotid artery and laryngeal involvement.
  • At two years follow-up, local progression was controlled by palliative chemotherapy.
  • DISCUSSION: For most authors, the risk of recurrent infections is the main reason for surgical resection of a thyroglossal duct cyst during childhood.
  • It is rather uncommon for carcinoma to develop on a thyroglossal duct cyst.
  • We discuss treatment in the event of malignant degeneration.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Thyroglossal Cyst / pathology. Thyroglossal Cyst / radiography
  • [MeSH-minor] Carotid Arteries / pathology. Combined Modality Therapy. Female. Humans. Larynx / pathology. Middle Aged. Neoplasm Invasiveness. Pain. Postoperative Care. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15711485.001).
  • [ISSN] 0003-438X
  • [Journal-full-title] Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Société d'oto-laryngologie des hôpitaux de Paris
  • [ISO-abbreviation] Ann Otolaryngol Chir Cervicofac
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


12. Yin M, Ishikawa K, Honda K, Arakawa T, Harabuchi Y, Nagabashi T, Fukuda S, Taira A, Himi T, Nakamura N, Tanaka K, Ichinohe M, Shinkawa H, Nakada Y, Sato H, Shiga K, Kobayashi T, Watanabe T, Aoyagi M, Ogawa H, Omori K: Analysis of 95 cases of squamous cell carcinoma of the external and middle ear. Auris Nasus Larynx; 2006 Sep;33(3):251-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of 95 cases of squamous cell carcinoma of the external and middle ear.
  • OBJECTIVE: To analyze the clinical characteristics, 5-year survival, and prognostic factors of squamous cell carcinoma (SCC) of the external and middle ear.
  • Ninety five cases of patients from 10 institutions were reviewed on their age and sex distribution, initial complaints, stages, tumor locations, treatments, and outcomes.
  • RESULTS: This disease seems to appear in the elderly with a peak age of 50-69 years.
  • The initial complaints were not typical, while 12.6% of patients presented a history of recurrent otitis externa or chronic otitis media.
  • SCC in stages I and II was susceptible to each therapeutic strategy with a 5-year survival of 100%.
  • Operation combined with radiotherapy and/or chemotherapy was the major treatment for stages III and IV SCC, while radiotherapy and chemotherapy were applied mainly for those who had been considered inappropriate for operation.
  • The overall survival was 67.2% for stage III and 29.5% for stage IV, and operation with pathologically tumor free margin could improve the survival to 72.7% when combined with radio- and chemotherapy.
  • Early diagnosis and treatment were important because SCC in the earlier stage is susceptible to be cured.
  • For tumors of advanced stage, operation should be performed with pathologically tumor free margin, and operation combined with radiotherapy and chemotherapy could improve the survival.
  • [MeSH-major] Carcinoma, Squamous Cell / epidemiology. Ear Neoplasms / epidemiology. Ear, External. Ear, Middle

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16431060.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


13. Levine MA, Saunders JR, Zinreich E, Kunar D, Price J, Hirata RM, Williams M: Concurrent chemoradiation therapy for advanced head and neck squamous cell carcinoma (HNSCC) in a community hospital. J Clin Oncol; 2004 Jul 15;22(14_suppl):5558

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemoradiation therapy for advanced head and neck squamous cell carcinoma (HNSCC) in a community hospital.
  • : 5558 Background: Concurrent chemotherapy and radiation therapy have made organ preservation feasible in patients with advanced head and neck squamous cell carcinoma.
  • This study evaluates the use of chemotherapy with hyperfractionated radiation therapy in a community hospital and the importance of elective lymph node dissection for N2 and N3 patients.
  • METHODS: Forty-six patients with HNSCC stage III and IV (42/46 male, 35/46 oropharynx, 4 hypopharynx, 7 larynx, 25 N0-1, 21 N2-3) were treated.
  • Hyperfractionated radiation therapy was administered twice daily with an interval of at least six hours and a total dose of 7000cGy to the primary site and 5-6000cGy to the adjacent lymph node bearing areas.
  • Chemotherapy was administered during weeks 1 and 6 of radiation therapy and consisted of cis-platin 12mg/M2 IVPB days 1-5 and 5-fluorouracil 600mg/M2 continuous IV infusion over 20 hours days 1-5.
  • Two pts died in remission from intercurrent illnesses more than 11 months after completion of therapy.
  • Of the remaining 44 pts, 38 remain NED (86%) (3 pts died from recurrent disease, 2 pts recurred locally and were salvaged surgically, one is alive with metastatic disease).
  • TOXICITY: short term, all pts developed confluent mucositis but hospitalization for dehydration or infection was rare; long term, mouth dryness was common but manageable and most pts were PEG independent within three months of completion of therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013960.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Caudell JJ, Schaner PE, Desmond RA, Meredith RF, Spencer SA, Bonner JA: Dosimetric factors associated with long-term dysphagia after definitive radiotherapy for squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys; 2010 Feb 1;76(2):403-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dosimetric factors associated with long-term dysphagia after definitive radiotherapy for squamous cell carcinoma of the head and neck.
  • PURPOSE: Intensification of radiotherapy and chemotherapy for head-and-neck cancer may lead to increased rates of dysphagia.
  • METHODS AND MATERIALS: From an institutional database, 83 patients were identified who underwent definitive intensity-modulated radiotherapy for squamous cell carcinoma of the head and neck, after exclusion of those who were treated for a second or recurrent head-and-neck primary lesion, had locoregional recurrence at any time, had less than 12 months of follow-up, or had postoperative radiotherapy.
  • RESULTS: Mean dose greater than 41 Gy and volume receiving 60 Gy (V(60)) greater than 24% to the larynx were significantly associated with PEG tube dependence and aspiration.
  • CONCLUSIONS: Doses to the larynx and pharyngeal constrictors predicted long-term swallowing complications, even when controlled for other clinical factors.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Deglutition Disorders / etiology. Head and Neck Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated / adverse effects
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Catheterization / utilization. Deglutition. Esophageal Stenosis / etiology. Esophageal Stenosis / therapy. Female. Gastrostomy / utilization. Humans. Male. Middle Aged. Pharyngeal Diseases / etiology. Pharyngeal Diseases / therapy. Radiotherapy Dosage. Retrospective Studies. Tumor Burden. Young Adult


15. Chen YF, Chen FJ, Yang AK, Zeng ZY, Song M, Li QL: [Clinical characteristics and multivariate analysis of prognostic factors in recurrent laryngeal carcinoma]. Ai Zheng; 2004 May;23(5):584-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics and multivariate analysis of prognostic factors in recurrent laryngeal carcinoma].
  • BACKGROUND & OBJECTIVE: The recurrence is an important factor affecting the prognosis of laryngeal carcinoma.
  • There are few reports on the clinical characteristics and the prognostic factors of recurrent laryngeal carcinoma.
  • The purpose of this study was to analyze the clinical features and prognostic factors of recurrent laryngeal carcinoma.
  • METHODS: The data of 80 patients with recurrent laryngeal carcinoma between 1990 and 1997 were retrospectively investigated.
  • The 3-year and 5-year overall survival rates for patients with recurrent laryngeal carcinoma were 50.6% and 34.6%, respectively.
  • The 5-year disease-specific survival rates for the patients treated with surgery, surgery + radiotherapy, and surgery +chemotherapy (30 cases) was 73%.
  • The recurrence of laryngeal carcinoma were developed within 1-156 months, the median time of recurrence was 11 months; there were 36 locoregional recurrence, 36 neck lymph node recurrence, 4 locoregional recurrence associated with neck lymph node recurrence, 1 locoregional recurrence associated with distant metastases, 3 neck lymph node recurrence associated with distant metastases.
  • Univariate analysis revealed that the factors impacting the prognosis were recurrent site, duration of recurrence gaps, treatment modality of recurrence, and age (P< 0.05).
  • The neck lymph node recurrence group, peristomal recurrence group, distant metastases group, radiotherapy and chemotherapy after recurrence group had a poorer prognosis than locoregional recurrence group, larynx recurrence group, without distant metastases group, and surgery group (P< 0.05).
  • Multivariate analysis showed that age > or =60 years old, duration of recurrence gap < 12 months, distant metastases and radiotherapy or chemotherapy modality after recurrence were independently associated with decreased survival rates (P< 0.05).
  • CONCLUSION: Surgery or surgery dominated multi-modality therapy was the principal treatment modality for recurrence laryngeal carcinoma.
  • Age > or =60 years old, duration of recurrence gap < 12 months, distant metastases and salvage therapy by radiotherapy and chemotherapy but not surgery were independent factors affecting the prognosis.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Laryngeal Neoplasms / therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Adult. Age Factors. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Laryngectomy / methods. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neck Dissection. Prognosis. Proportional Hazards Models. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15142460.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


16. Shimane T, Mori T, Ono T, Monden T, Furuya A, Kobayashi S, Sanbe T, Suzaki H: [Two cases of head and neck squamous cell carcinoma in which S-1 administration resulted in long-term sustained QOL]. Gan To Kagaku Ryoho; 2009 Jul;36(7):1141-4
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of head and neck squamous cell carcinoma in which S-1 administration resulted in long-term sustained QOL].
  • Palliative treatments are applied for older adult cases that are not indicated for either surgery or potential chemotherapy, as well as in cases with unresectable primary lesions, distant metastases, and serious complications among head and neck cancer cases.
  • There is no established treatment for such cases, and therefore treatment has to be selected on a case-by-case basis.
  • Two cases showing sustained QOL after long administration of S-1 are presented in this paper.
  • The second is a 70- year-old male patient who had recurrent cancer of the larynx (T1N0M0, stage I) after primary treatment.
  • Regulating the dosage and intervals of S-1 enabled the patients in both cases to survive with cancer as outpatients for 2 years and 2 months after the initial visit (1 year and 10 months from the start of the administration of S-1) in the former case and 3 years from the initial visit (2 years and 1 month from the start of the administration of S-1) in the latter case.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Hypopharyngeal Neoplasms / drug therapy. Laryngeal Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Aged, 80 and over. Drug Combinations. Humans. Male. Quality of Life

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620804.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


17. Miura K, Kum Y, Han G, Tsutsui Y: Radiation-induced laryngeal angiosarcoma after cervical tuberculosis and squamous cell carcinoma: case report and review of the literature. Pathol Int; 2003 Oct;53(10):710-5
Genetic Alliance. consumer health - Tuberculosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation-induced laryngeal angiosarcoma after cervical tuberculosis and squamous cell carcinoma: case report and review of the literature.
  • Primary laryngeal angiosarcoma (LA) is quite rare with only 13 cases reported in English literature to date.
  • A case of LA after radiation therapy for tuberculosis and squamous cell carcinoma is reported.
  • A 70-year-old woman had a history of radiation therapy for left cervical tuberculosis at the age of 28.
  • At 60 years of age a squamous cell carcinoma of the larynx was found and chemotherapy and radiotherapy, consisting of a total dose of 68.4 Gy, were administered.
  • At the age of 68, recurrent squamous cell carcinoma was suspected from several biopsies, and a total laryngectomy with right thyroidectomy was performed.
  • No residual squamous cell carcinoma was found.
  • In the present case, it was suspected that irradiation to the larynx for cervical tuberculosis and squamous cell carcinoma induced angiosarcoma.
  • The patient was still alive despite multiple skin and soft tissue metastasis 3 years and 6 months after the radical operation.
  • Distinction of postirradiation angiosarcoma from pseudoangiosarcomatous carcinoma seems difficult but is important because irradiation is not effective and an initial radical surgery is the only effective treatment.
  • Although irradiation is a common treatment for laryngeal squamous cell carcinoma, this is only the second case of radiation-induced LA in English literature.
  • [MeSH-major] Carcinoma, Squamous Cell / etiology. Hemangiosarcoma / etiology. Laryngeal Neoplasms / etiology. Neoplasms, Multiple Primary / etiology. Neoplasms, Radiation-Induced / etiology. Tuberculosis, Lymph Node / radiotherapy
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Laryngectomy. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14516323.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor
  • [Number-of-references] 30
  •  go-up   go-down


18. Lorenz KJ, Maier H: [Squamous cell carcinoma of the head and neck. Photodynamic therapy with Foscan]. HNO; 2008 Apr;56(4):402-9
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Squamous cell carcinoma of the head and neck. Photodynamic therapy with Foscan].
  • [Transliterated title] Plattenepithelkarzinome im Kopf-Hals-Bereich. Photodynamische Therapie mit Foscan.
  • INTRODUCTION: Photodynamic therapy (PDT) is a relatively new method of treating superficial tumours of the skin or mucous membranes.
  • After the injection of a photosensitiser, the tumour area is exposed to non-thermal laser light.
  • PATIENTS AND METHODS: From November 2004 to February 2006, a total of 24 patients with recurrent or secondary tumours after squamous cell carcinoma of the head and neck were treated with PDT at the German Armed Forces Hospital in Ulm after other treatment options had failed.
  • Three patients did not respond to treatment.
  • The mean duration of overall survival was 305.7 days (+/-199.4) after completion of treatment.
  • CONCLUSIONS: Photodynamic therapy is an important treatment option for patients who develop recurrent or secondary tumours after squamous cell carcinoma of the upper aerodigestive tract and fail to respond to other treatments.
  • In addition, PDT may play a role in the primary treatment of superficial tumours of the oral cavity, pharynx and larynx in the future.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Mesoporphyrins / therapeutic use. Photochemotherapy / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Disease-Free Survival. Female. Humans. Male. Middle Aged. Photosensitizing Agents / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Laser Med Surg. 1996 Oct;14(5):239-44 [9612189.001]
  • [Cites] Eur J Cancer Clin Oncol. 1982 Aug;18(8):707-12 [6891321.001]
  • [Cites] Methods Enzymol. 1984;105:36-47 [6727677.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2653-8 [16763279.001]
  • [Cites] J Clin Oncol. 1992 Aug;10(8):1245-51 [1634913.001]
  • [Cites] HNO. 1999 Oct;47(10):885-92 [10550372.001]
  • [Cites] HNO. 1995 Jun;43(6):364-70 [7642397.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Apr;12(4):573-8 [3516952.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Jul;129(7):709-11 [12874068.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 May;127(5):489-93 [11346422.001]
  • [Cites] Onkologie. 2003 Dec;26(6):568-72 [14709932.001]
  • [Cites] HNO. 2004 Feb;52(2):175-192 [28246683.001]
  • [Cites] Head Neck. 2004 Mar;26(3):232-40 [14999798.001]
  • [Cites] N Engl J Med. 2001 Dec 27;345(26):1890-900 [11756581.001]
  • [Cites] Oncology. 2002;63(2):145-50 [12239449.001]
  • [Cites] Prog Clin Biol Res. 1984;170:3-18 [6531365.001]
  • [Cites] Br J Cancer. 1992 Mar;65(3):309-10 [1558782.001]
  • [Cites] J Laryngol Otol. 1993 Dec;107(12):1140-5 [8289004.001]
  • [Cites] Int J Cancer. 2004 Aug 10;111(1):138-46 [15185355.001]
  • [Cites] HNO. 1999 Dec;47(12):1058-62 [10654183.001]
  • [Cites] Head Neck Surg. 1985 Sep-Oct;8(1):9-20 [4066369.001]
  • [Cites] Onkologie. 2001 Jun;24(3):230-7 [11455215.001]
  • [Cites] Radiother Oncol. 1995 Aug;36(2):94-100 [7501817.001]
  • [Cites] Laryngoscope. 1994 Apr;104(4):399-403 [8164476.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2000;257(3):164-7 [10839492.001]
  • [Cites] Laryngorhinootologie. 2005 Oct;84(10):725-32 [16231239.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1996 Nov;122(11):1261-5 [8906063.001]
  • (PMID = 17516041.001).
  • [ISSN] 1433-0458
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Mesoporphyrins; 0 / Photosensitizing Agents; FU21S769PF / temoporfin
  •  go-up   go-down


19. Liu WS, Tang PZ, Qi YF, Xu ZG, Li ZJ: [Clinical analysis of 57 patients with poorly differentiated carcinomas of the supraglottic larynx]. Zhonghua Er Bi Yan Hou Ke Za Zhi; 2004 Sep;39(9):562-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 57 patients with poorly differentiated carcinomas of the supraglottic larynx].
  • OBJECTIVE: To investigate the clinical characteristics, treatment and prognosis for poorly differentiated supraglottic carcinomas.
  • Of the 57 patients, 25 were treated with surgery alone, 9 with irradiation alone, 14 with surgery following preoperative radiation, 7 with postoperative radiation following surgery and 2 with surgery following preoperative chemotherapy.
  • RESULTS: The overall 5-year survival rate, accumulated cervical metastasis rate, metastasis rate of bilateral side of neck, distant metastasis rate, cervical recurrent rate and locally recurrent rate were 47.4% (27/57), 63.2% (36/57), 24.6% (14/57), 21.1% (12/57), 28.1% (16/57) and 10.5% (6/57), respectively.
  • In addition, the local recurrent rate for partial laryngectomy was 12% (3/25).
  • CONCLUSIONS: Poorly differentiated carcinomas of the supraglottic larynx had characteristics of the advanced stage in terms of earlier lymph node metastasis and a relatively high rate of cervical and distant metastasis.
  • Surgery was still the primary treatment for this disease and it was feasible to perform partial laryngectomy on certain patients.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Glottis / surgery. Laryngeal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Laryngectomy. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15606009.001).
  • [ISSN] 0412-3948
  • [Journal-full-title] Zhonghua er bi yan hou ke za zhi
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


20. Bourhis J, Lefebvre JL, Vermorken JB: Cetuximab in the management of locoregionally advanced head and neck cancer: expanding the treatment options? Eur J Cancer; 2010 Jul;46(11):1979-89
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cetuximab in the management of locoregionally advanced head and neck cancer: expanding the treatment options?
  • The treatment of locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN) has evolved in recent years as a consequence of a better understanding of the potential benefits associated with altered radiation fractionation regimens, concurrently administered chemotherapy and radiotherapy (chemoradiotherapy) and induction chemotherapy.
  • Concurrent chemoradiotherapy is a treatment option for technically resectable disease, where functional morbidity precludes the use of surgery.
  • Induction chemotherapy followed by radiotherapy may also be used in this setting, and has been validated for larynx preservation.
  • Concurrent chemoradiotherapy is a standard treatment approach for medically fit patients with locoregionally advanced unresectable disease.
  • However, the toxicity burden of additional chemotherapy in both the concurrent chemoradiotherapy and induction chemotherapy settings can have implications for treatment compliance and may impede the administration of chemotherapy and/or radiotherapy to schedule.
  • The epidermal growth factor receptor (EGFR)-targeted IgG1 monoclonal antibody, cetuximab (Erbitux), has shown significant clinical benefits in the treatment of both locoregionally advanced and recurrent and/or metastatic SCCHN.
  • Taken together, these data support an important role for cetuximab in the treatment paradigm for locoregionally advanced SCCHN.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Cetuximab. Combined Modality Therapy. Humans. Papillomavirus Infections / complications

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20561781.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; PQX0D8J21J / Cetuximab
  •  go-up   go-down


21. Wang MY, Teitelbaum GP, Loskota WJ, Eng D, Albuquerque F, Gruen JP: Brachial plexus catheter reservoir for the treatment of upper-extremity cancer pain: technical case report. Neurosurgery; 2000 Apr;46(4):1009-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brachial plexus catheter reservoir for the treatment of upper-extremity cancer pain: technical case report.
  • Because the analgesia is short-lived, however, repeated invasive treatments are necessary.
  • We describe the implantation of a catheter reservoir system, in which anesthetic injections through a subcutaneous port resulted in anesthetic infiltration of the brachial plexus.
  • CLINICAL PRESENTATION: A 47-year-old Hispanic man with squamous cell carcinoma of the larynx had undergone surgical resection, radiation treatment, and chemotherapy.
  • Two years later, he had locally recurrent disease involving the brachial plexus, neck, and chest wall.
  • TECHNIQUE: The brachial plexus was localized percutaneously with a needle electrode stimulator.
  • With use of the Seldinger technique, two Silastic catheters were placed within the brachial plexus and attached with a "Y" connector to a reservoir.
  • After the treatments were initiated, the patient reported improved sleep and an improvement in his quality of life.
  • [MeSH-major] Arm / physiopathology. Brachial Plexus / physiopathology. Carcinoma, Squamous Cell / drug therapy. Drug Delivery Systems. Nervous System Neoplasms / drug therapy. Palliative Care / methods
  • [MeSH-minor] Anesthetics, Local / administration & dosage. Anesthetics, Local / therapeutic use. Bupivacaine / administration & dosage. Bupivacaine / therapeutic use. Catheterization. Humans. Male. Middle Aged. Pain / drug therapy

  • MedlinePlus Health Information. consumer health - Arm Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10764282.001).
  • [ISSN] 0148-396X
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Anesthetics, Local; Y8335394RO / Bupivacaine
  •  go-up   go-down


22. Kubota A, Furukawa M, Kawano T, Komatsu M: [Nedaplatin for recurrent cancer of the head and neck]. Nihon Jibiinkoka Gakkai Kaiho; 2004 May;107(5):475-82
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Nedaplatin for recurrent cancer of the head and neck].
  • This study was undertaken to evaluate the clinical efficacy and toxicity of Nedaplatin (254-S) alone or combined for UFT for recurrent head and neck cancers in an outpatient setting.
  • Thirty-two patients, previously treated, (30 men and 2 women, mean age 59 years, twenty one with loco-regional recurrence and 11 with distant metastasis, 29 with squamous cell carcinoma, 2 with adenocarcinoma and one with adenoid cystic carcinoma) were treated with Nedaplatin (254-S) alone or combined with UFT.
  • The primary site was identified in the oropharynx in 8 patients, oral cavity in 7, larynx in 5, nasopharynx in 4, hypopharynx in 3, sinuses in one, parotid in one, and unknown primary in one patient.
  • Treatment with 254-S alone or combined UFT-E could be conducted in an outpatient setting and was able to improve the overall survival rate for recurrent head and neck cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Head and Neck Neoplasms / drug therapy. Organoplatinum Compounds / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Adenoid Cystic / drug therapy. Carcinoma, Squamous Cell / drug therapy. Female. Humans. Male. Middle Aged. Survival Rate. Tegafur / administration & dosage. Uracil / administration & dosage

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15198007.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 8UQ3W6JXAN / nedaplatin; 1-UFT protocol
  •  go-up   go-down


23. Kovács AF, Eberlein K, Hülsmann T: Organ preservation treatment using TPF-a pilot study in patients with advanced primary and recurrent cancer of the oral cavity and the maxillary sinus. Oral Maxillofac Surg; 2009 Jun;13(2):87-93
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organ preservation treatment using TPF-a pilot study in patients with advanced primary and recurrent cancer of the oral cavity and the maxillary sinus.
  • PURPOSE: Induction chemotherapy with Taxotere, cisplatin, and 5-fluororacil (TPF) was mainly used in hypopharyngeal and laryngeal cancer patients for larynx preservation.
  • PATIENTS AND METHODS: Between 2003 and 2008, 21 patients (18 male, three female; mean age 58 years; 15 patients Eastern Cooperative Oncology Group > or =1) suffering from advanced squamous cell cancers of the oral cavity (seven primaries, eight locoregional recurrences) and the maxillary sinus (six patients) were prospectively treated with three cycles of TPF (q3w) and were scheduled to undergo definitive chemoradiation.
  • Reasons for incomplete treatment were tumor progression, edema, seizure, bad general condition, sepsis, pneumonia (each once).
  • The infections led to two treatment-related deaths (9.5%).
  • Ten patients underwent a definitive chemoradiation or radiation (47.6%).
  • After a mean observation time of 17 months, nine patients are alive; one of them developed a local recurrence.
  • CONCLUSIONS: Chemotherapy with TPF is a highly effective treatment with considerable toxicity that needs special expertise which is best assured in a multidisciplinary setting.
  • Pretreated recurrent cancers demonstrated bad response.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Maxillary Sinus Neoplasms / drug therapy. Mouth Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / adverse effects. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cisplatin / therapeutic use. Disease Progression. Feasibility Studies. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Fluorouracil / therapeutic use. Follow-Up Studies. Humans. Leukopenia / chemically induced. Male. Middle Aged. Neoplasm Staging. Neutropenia / chemically induced. Opportunistic Infections / etiology. Pilot Projects. Prospective Studies. Radiotherapy, Adjuvant. Remission Induction. Stomatitis / chemically induced. Survival Rate. Taxoids / administration & dosage. Taxoids / adverse effects. Taxoids / therapeutic use

  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Sinus cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2009 May;20(5):921-7 [19179556.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2873-8 [16782926.001]
  • [Cites] Am J Clin Oncol. 2002 Oct;25(5):485-8 [12393990.001]
  • [Cites] Mund Kiefer Gesichtschir. 2006 May;10(3):168-77 [16604330.001]
  • [Cites] Oral Oncol. 2006 Aug;42(7):675-84 [16731029.001]
  • [Cites] N Engl J Med. 2007 Oct 25;357(17):1695-704 [17960012.001]
  • [Cites] N Engl J Med. 2007 Oct 25;357(17):1705-15 [17960013.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] Otolaryngol Head Neck Surg. 2007 Jun;136(6):1003-9 [17547996.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):481-7 [15145166.001]
  • [Cites] Anticancer Res. 2006 Jan-Feb;26(1B):585-90 [16739325.001]
  • [Cites] Otolaryngol Clin North Am. 2005 Feb;38(1):75-85, viii [15649500.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):88-95 [15625363.001]
  • (PMID = 19430823.001).
  • [ISSN] 1865-1550
  • [Journal-full-title] Oral and maxillofacial surgery
  • [ISO-abbreviation] Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Taxoids; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; TPF protocol
  •  go-up   go-down


24. Lorenz KJ, Maier H: Photodynamic therapy with meta-tetrahydroxyphenylchlorin (Foscan) in the management of squamous cell carcinoma of the head and neck: experience with 35 patients. Eur Arch Otorhinolaryngol; 2009 Dec;266(12):1937-44
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy with meta-tetrahydroxyphenylchlorin (Foscan) in the management of squamous cell carcinoma of the head and neck: experience with 35 patients.
  • Photodynamic therapy (PDT) is a relatively new method of treating superficial tumours of the skin and mucosa.
  • After the injection of a photosensitizing agent, the tumour area is exposed to non-thermal laser light.
  • From November 2003 to July 2007, a total of 35 patients with recurrent squamous cell carcinoma or secondary tumours of the head and neck region were treated with PDT at the German Armed Forces Hospital in Ulm.
  • These patients had failed or found unsuitable for other treatments.
  • Four patients (11.5%) did not respond to PDT treatment.
  • The mean duration of overall survival was 401.45 (+/-321.2) days, median was 356 after the completion of treatment.
  • None of the patient developed serious complications.
  • Photodynamic therapy is an important treatment option for patients who present with recurrent carcinoma or secondary tumours of the upper aerodigestive tract and who have failed or unsuitable for other treatments.
  • Due to the excellent treatment results that have been achieved so far, PDT may in the future also play a role in the primary treatment of superficial tumours of the oral cavity, pharynx and larynx.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Mesoporphyrins / therapeutic use. Photochemotherapy / methods. Photosensitizing Agents / therapeutic use
  • [MeSH-minor] Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Germany / epidemiology. Humans. Injections, Intravenous. Magnetic Resonance Imaging. Male. Middle Aged. Positron-Emission Tomography. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Laser Med Surg. 1996 Oct;14(5):239-44 [9612189.001]
  • [Cites] Eur J Cancer Clin Oncol. 1982 Aug;18(8):707-12 [6891321.001]
  • [Cites] Methods Enzymol. 1984;105:36-47 [6727677.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2653-8 [16763279.001]
  • [Cites] J Clin Oncol. 1992 Aug;10(8):1245-51 [1634913.001]
  • [Cites] HNO. 1999 Oct;47(10):885-92 [10550372.001]
  • [Cites] HNO. 1995 Jun;43(6):364-70 [7642397.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Apr;12(4):573-8 [3516952.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Jul;129(7):709-11 [12874068.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 May;127(5):489-93 [11346422.001]
  • [Cites] Onkologie. 2003 Dec;26(6):568-72 [14709932.001]
  • [Cites] HNO. 2004 Feb;52(2):175-192 [28246683.001]
  • [Cites] Head Neck. 2004 Mar;26(3):232-40 [14999798.001]
  • [Cites] N Engl J Med. 2001 Dec 27;345(26):1890-900 [11756581.001]
  • [Cites] Oncology. 2002;63(2):145-50 [12239449.001]
  • [Cites] J Laryngol Otol. 1993 Dec;107(12):1140-5 [8289004.001]
  • [Cites] Int J Cancer. 2004 Aug 10;111(1):138-46 [15185355.001]
  • [Cites] HNO. 1999 Dec;47(12):1058-62 [10654183.001]
  • [Cites] Oral Oncol. 2004 Apr;40(4):372-82 [14969816.001]
  • [Cites] Onkologie. 2001 Jun;24(3):230-7 [11455215.001]
  • [Cites] Radiother Oncol. 1995 Aug;36(2):94-100 [7501817.001]
  • [Cites] Laryngoscope. 1994 Apr;104(4):399-403 [8164476.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2000;257(3):164-7 [10839492.001]
  • [Cites] N Engl J Med. 2008 Sep 11;359(11):1116-27 [18784101.001]
  • [Cites] Int J Cancer. 1995 Oct 9;63(2):198-204 [7591204.001]
  • [Cites] Laryngorhinootologie. 2005 Oct;84(10):725-32 [16231239.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1996 Nov;122(11):1261-5 [8906063.001]
  • [Cites] Br J Cancer. 2002 Dec 2;87(12):1470-8 [12454779.001]
  • (PMID = 19290535.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Mesoporphyrins; 0 / Photosensitizing Agents; FU21S769PF / temoporfin
  •  go-up   go-down


25. Abo H, Tsukuda M, Matsuda H, Horiuchi C, Taguchi T, Watanabe M, Niho T: [Successful treatment results of S-1 administration in 2 patients, one with a remnant tumor of the larynx and metastatic tumors to the lung, and another with a metastatic tumor in the neck from the hypopharynx]. Gan To Kagaku Ryoho; 2009 Oct;36(10):1707-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful treatment results of S-1 administration in 2 patients, one with a remnant tumor of the larynx and metastatic tumors to the lung, and another with a metastatic tumor in the neck from the hypopharynx].
  • We report two successful remnant and recurrent cases of head and neck cancer treated with S-1.
  • Case 1, a 52-year-old man, was diagnosed as supraglottic laryngeal carcinoma (T3N2cM0, squamous cell carcinoma: SCC) on January 25, 2000, and concurrent chemoradiotherapy (CCRT) was applied.
  • After the treatment, a remnant tumor in the larynx was found by biopsy.
  • Pulmonary metastasis was detected by chest CT on June 14, 2001, and the administration of S-1 was started.
  • The administration of S-1 is still continuing and remnant tumors have not been found.
  • Case 2, a 76-year-old man, was diagnosed with hypopharyngeal carcinoma (T3N2bM0, SCC) on December 14, 2001, and CCRT was applied resulting in CR in the hypopharynx and the neck.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Hypopharyngeal Neoplasms / drug therapy. Laryngeal Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Drug Combinations. Humans. Male. Middle Aged. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19838032.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


26. Patel RS, Makitie AA, Goldstein DP, Gullane PJ, Brown D, Irish J, Gilbert RW: Morbidity and functional outcomes following gastro-omental free flap reconstruction of circumferential pharyngeal defects. Head Neck; 2009 May;31(5):655-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In patients with extensive soft tissue fibrosis requiring circumferential pharyngeal reconstruction following definitive radiotherapy and/or chemotherapy, we take advantage of abundant omental progenitor factors in the tubed gastro-omental free flap.
  • METHODS: Review of 11 patients (median follow-up, 2.8 years) undergoing total pharyngolaryngectomy following organ preservation protocols for recurrent squamous cell carcinoma (n = 9) and stricture (n = 2).
  • [MeSH-minor] Aged. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / surgery. Constriction, Pathologic / surgery. Female. Fistula / etiology. Fistula / surgery. Follow-Up Studies. Gastric Mucosa / blood supply. Gastric Mucosa / transplantation. Gastric Outlet Obstruction / etiology. Gastric Outlet Obstruction / therapy. Hematoma / etiology. Hematoma / surgery. Hernia, Abdominal / etiology. Hernia, Abdominal / surgery. Humans. Hypopharyngeal Neoplasms / mortality. Hypopharyngeal Neoplasms / surgery. Laryngeal Neoplasms / mortality. Laryngeal Neoplasms / surgery. Larynx, Artificial. Length of Stay. Male. Middle Aged. Neoplasm Recurrence, Local / surgery. Omentum / blood supply. Omentum / transplantation. Pulmonary Embolism / drug therapy. Pulmonary Embolism / surgery. Salvage Therapy. Surgical Wound Dehiscence / etiology. Surgical Wound Dehiscence / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19260110.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Kasperts N, Slotman B, Leemans CR, Langendijk JA: A review on re-irradiation for recurrent and second primary head and neck cancer. Oral Oncol; 2005 Mar;41(3):225-43
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A review on re-irradiation for recurrent and second primary head and neck cancer.
  • The purpose of this paper is to review the results of studies regarding radiation as primary or adjuvant treatment modality for head and neck recurrences or second primary tumours (SPT) in previously irradiated areas, with emphasis on acute and late radiation induced morbidity, locoregional control and survival.
  • (1) re-irradiation for locoregional recurrent disease or SPT in the head and neck region, (2) squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx and larynx, and (3) a minimum of 10 patients included in the study.
  • Studies were divided in four categories, including (1) external beam re-irradiation, (2) re-irradiation with brachytherapy, (3) re-irradiation in combination with chemotherapy and (4) postoperative re-irradiation.
  • Most studies were retrospective using heterogeneous treatment regimens and including heterogeneous groups of patients.
  • High dose reirradiation as salvage treatment in case of recurrent or second primary head and neck cancer should be considered, particularly when salvage surgery is not feasible.
  • Although long term survivors are reported is some studies, the relatively high incidence of treatment-related morbidity emphasize the need for further optimisation in order to improve locoregional control and reduce the risk on late morbidity.
  • [MeSH-minor] Brachytherapy. Combined Modality Therapy. Humans. Morbidity. Retreatment. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Oral Oncol. 2005 Oct;41(9):953-4 [15935725.001]
  • (PMID = 15743686.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 61
  •  go-up   go-down


28. Lin HW, Richmon JD, Emerick KS, de Venecia RK, Zeitels SM, Faquin WC, Lin DT: Malignant transformation of a highly aggressive human papillomavirus type 11-associated recurrent respiratory papillomatosis. Am J Otolaryngol; 2010 Jul-Aug;31(4):291-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of a highly aggressive human papillomavirus type 11-associated recurrent respiratory papillomatosis.
  • OBJECTIVE: The objective is to present an uncommon case of squamous cell carcinoma (SCC) arising from extensive recurrent respiratory papillomatosis (RRP) involving the upper and lower airway and temporal bone.
  • METHODS: We describe a case of a 24-year-old woman with a history of human papillomavirus (HPV) type 11 since childhood originating in the larynx and trachea, then progressing to involve the distal pulmonary alveoli and right middle ear through the eustachian tube.
  • Papillomatous growth was treated with multiple surgeries including laser cytoreduction of laryngotracheal papillomatosis and radical mastoidectomy, followed by a trial of chemotherapy.
  • Despite this aggressive treatment regimen, papillomatous growth progressed with recurrence in the right eustachian tube, middle ear, and mastoid eventually extending to involve the calvaria and scalp.
  • RESULTS: The patient underwent a composite resection of involved tissues, including the scalp, auricle, and lateral temporal bone, with reconstruction using a latissimus dorsi free flap.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Human papillomavirus 11. Papilloma / pathology. Respiratory Tract Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Disease Progression. Female. Humans. Neoplasm Recurrence, Local. Tomography, X-Ray Computed. Young Adult

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20015762.001).
  • [ISSN] 1532-818X
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Wakisaka N, Murono S, Kondo S, Furukawa M, Yoshizaki T: Post-operative pharyngocutaneous fistula after laryngectomy. Auris Nasus Larynx; 2008 Jun;35(2):203-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Although organ-preserving radiotherapy or chemoradiotherapy has offered good locoregional control, many patients still experience recurrent disease requiring salvage laryngectomy.
  • Here, we evaluated the cause of PCF after laryngectomy, with special emphasis on radiotherapy and/or chemotherapy.
  • PATIENTS AND METHODS: A total of 63 consecutive patients undergoing salvage total laryngectomy for squamous cell carcinoma of the larynx at Kanazawa University Hospital from 1990 to 2005 were reviewed.
  • RESULTS: Overall, 17 of the 63 patients (27.0%) developed PCF after laryngectomy.
  • CONCLUSIONS: Although radiotherapy or chemotherapy has only a limited impact on PCF formation, concurrent chemoradiotherapy significantly increases PCF formation.
  • The addition of chemotherapy to irradiation delays PCF closure.
  • [MeSH-minor] Carcinoma, Squamous Cell / therapy. Chemotherapy, Adjuvant / adverse effects. Female. Humans. Laryngeal Neoplasms / therapy. Male. Middle Aged. Postoperative Complications. Radiotherapy, Adjuvant / adverse effects. Salvage Therapy

  • MedlinePlus Health Information. consumer health - Throat Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17826021.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


30. Agra IM, Carvalho AL, Pontes E, Campos OD, Ulbrich FS, Magrin J, Kowalski LP: Postoperative complications after en bloc salvage surgery for head and neck cancer. Arch Otolaryngol Head Neck Surg; 2003 Dec;129(12):1317-21
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Only patients with recurrent head and neck squamous cell carcinoma undergoing en bloc salvage resection were eligible for the study.
  • RESULTS: The tumor location was the lip in 6 patients, oral cavity in 55, oropharynx in 31, larynx in 24, and hypopharynx in 8.
  • Previous treatment was surgery alone in 20 patients, radiotherapy alone in 68, surgery and radiotherapy in 21, and radiotherapy and chemotherapy in 14.
  • An additional patient received chemotherapy alone before salvage surgery.
  • The clinical stage of the recurrent tumor was I or II in 23 patients and III or IV in 101 patients.
  • The major factor associated with the overall occurrence of postoperative complications was the clinical stage of the recurrent tumor (P =.02).
  • The occurrence of minor complications correlated with the previously treated site, with complications occurring more often in patients undergoing locoregional vs local treatment (P =.04).
  • Major complications were associated with the time between initial treatment and salvage surgery (P =.05).
  • The clinical stage of the recurrent tumor and the previous site treated were the 2 major factors associated with the occurrence of postoperative complications.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Head and Neck Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Postoperative Complications / etiology. Salvage Therapy / adverse effects
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Length of Stay / statistics & numerical data. Logistic Models. Male. Middle Aged. Morbidity. Multivariate Analysis. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Factors. Survival Analysis. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14676158.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Wycliffe ND, Grover RS, Kim PD, Simental A Jr: Hypopharyngeal cancer. Top Magn Reson Imaging; 2007 Aug;18(4):243-58
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hypopharyngeal cancers are usually squamous cell carcinomas (SCCs) that has the worst prognosis among the head and neck cancers.
  • Overall, 5-year survival rate remains poor despite recent improvements in diagnostic imaging, radiation and chemotherapy, and improved surgical techniques.
  • The most important features determining prognosis are the size and extent of local spread of the primary carcinoma and the extent of involvement of regional lymph nodes.
  • Contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI) remain the mainstay of initial radiological evaluation of hypopharyngeal cancer.
  • Meticulous evaluation of the extent of the primary tumor with attention to spread to the subsites of the hypopharynx, larynx, and cartilage invasion are necessary for accurate staging.
  • After surgery and radiation therapy, it is difficult with CT and MR to differentiate residual and recurrent tumor from edema and scarring.
  • Fluorine 18-fluoro-deoxy-glucose -positron emission tomography (FDG-PET) has high sensitivity in detection of occult, residual, and recurrent tumors but has low specificity.
  • [MeSH-major] Hypopharyngeal Neoplasms / diagnosis. Hypopharyngeal Neoplasms / radiography. Hypopharynx / pathology. Magnetic Resonance Imaging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17893590.001).
  • [ISSN] 0899-3459
  • [Journal-full-title] Topics in magnetic resonance imaging : TMRI
  • [ISO-abbreviation] Top Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 138
  •  go-up   go-down


32. Biel MA: Photodynamic therapy of head and neck cancers. Methods Mol Biol; 2010;635:281-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy of head and neck cancers.
  • These patients include a mixture of presentations including primary, recurrent, and metastatic lesions.
  • The predominant histology is squamous cell carcinoma, but other histologies treated include mucosal melanoma, Kaposi's sarcoma, adenocarcinoma, metastatic breast carcinoma, and adenoid cystic carcinoma.
  • Several multi-institutional phase II clinical trials evaluating PDT treatment of head and neck cancers have demonstrated the efficacy of this minimally invasive therapy in the treatment of early oropharyngeal primary and recurrent cancers as well as the palliative treatment of refractory head and neck cancers.
  • Patients with early stage cancers or early recurrences in the oral cavity and larynx (Cis, T1, T2) tend to have an excellent response to PDT.
  • Of 518 patients treated with Cis, T1, or T2 cancers of the oral cavity, larynx, pharynx, and nasopharynx, 462 (89.1%) obtained a complete clinical response after one PDT treatment.
  • Laryngeal cancers, comprising 171 patients in this group, obtained a durable complete response rate of 89% with up to a 16-year follow-up.
  • Photodynamic therapy is as effective as conventional therapies for the treatment of early (Cis, T1, T2) squamous cell cancers of the head and neck.
  • It is also a promising therapy to be used in association with surgery to increase tumor-free margins and therefore increase cure rates.
  • [MeSH-major] Head and Neck Neoplasms / drug therapy. Photochemotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Randomized Controlled Trials as Topic. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20552353.001).
  • [ISSN] 1940-6029
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Cripps C, Winquist E, Devries MC, Stys-Norman D, Gilbert R, Head and Neck Cancer Disease Site Group: Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer. Curr Oncol; 2010 Jun;17(3):37-48
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
  • QUESTION: What are the benefits associated with the use of anti-epidermal growth factor receptor (anti-EGFR) therapies in squamous cell carcinoma of the head and neck (HNSCC)?
  • Anti-EGFR therapies of interest included cetuximab, gefitinib, lapatinib, zalutumumab, erlotinib, and panitumumab.
  • The most common histologic type is squamous cell carcinoma, and most common sites are the oral cavity, the oropharynx, the hypopharynx, and the larynx.
  • Worldwide, HNSCC is the sixth most common neoplasm, and despite advances in therapy, long-term survival in HNSCC patients is poor.
  • Primary surgery followed by chemoradiation, or primary chemoradiation, are the standard treatment options for patients with locally advanced (stages III-IVB) HNSCC; however, meta-analytic data indicate that the benefit of concurrent platinum-based chemotherapy disappears in patients over the age of 70 years.
  • Cetuximab is a monoclonal antibody approved for use in combination with radiation in the treatment of patients with untreated locally advanced HNSCC and as monotherapy for patients with recurrent or metastatic (stage IVC) HNSCC who have progressed on platinum-based therapy.
  • Given the interest in anti-EGFR agents in advanced HNSCC, the Head and Neck Cancer Disease Site Group (DSG) of Cancer Care Ontario's Program in Evidence-Based Care (PEBC) chose to systematically review the literature pertaining to this topic so as to develop evidence-based recommendations for treatment.
  • OUTCOMES: Outcomes of interest included overall and progression-free survival, quality of life, tumour response rate and duration, and the toxicity associated with the use of anti-EGFR therapies.
  • The randomized controlled trials (RCTS) involved three distinct patient populations: those with locally advanced HNSCC being treated for cure, those with incurable advanced recurrent or metastatic HNSCC being treated with first-line platinum-based chemotherapy, and those with incurable advanced recurrent or metastatic HNSCC who had disease progression despite, or who were unsuitable for, first-line platinum-based chemotherapy.
  • PRACTICE GUIDELINE: These recommendations apply to adult patients with locally advanced (nonmetastatic stages iii-ivb) or recurrent or metastatic (stage IVC) HNSCC.
  • Platinum-based chemoradiation remains the current standard of care for treatment of locally advanced HNSCC.
  • In patients with locally advanced HNSCC who are medically unsuitable for concurrent platinum based chemotherapy or who are over the age of 70 years (because concurrent chemotherapy does not appear to improve overall survival in this patient population), the addition of cetuximab to radical radiotherapy should be considered to improve overall survival, progression-free survival, and time to local recurrence.Cetuximab in combination with platinum-based combination chemotherapy is superior to chemotherapy alone in patients with recurrent or metastatic HNSCC, and is recommended to improve overall survival, progression-free survival, and response rate.The role of anti-EGFR therapies in the treatment of locally advanced HNSCC is currently under study in large randomized trials, and patients with HNSCC should continue to be offered clinical trials of novel agents aimed at improving outcomes.
  • However, five ongoing trials are investigating the effect of the addition of EGFR inhibitors concurrently with, before, or after chemoradiotherapy; those trials should provide direction about the best integration of cetuximab into standard treatment.
  • In patients with recurrent or metastatic HNSCC who experience progressive disease despite, or who are unsuitable for, first-line platinum-based chemotherapy, gefitinib at doses of 250 mg or 500 mg daily, compared with weekly methotrexate, did not increase median overall survival [hazard ratio (hr): 1.22; 96% confidence interval (ci): 0.95 to 1.57; p = 0.12 (for 250 mg daily vs. weekly methotrexate); hr: 1.12; 95% ci: 0.87 to 1.43; p = 0.39 (for 500 mg daily vs. weekly methotrexate)] or objective response rate (2.7% for 250 mg and 7.6% for 500 mg daily vs. 3.9% for weekly methotrexate, p > 0.05).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1995 Jul;72(1):123-8 [7599040.001]
  • [Cites] N Engl J Med. 2008 Oct 23;359(17):1757-65 [18946061.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):1226-31 [9508211.001]
  • [Cites] Eur J Cancer. 2000 Sep;36(14):1796-807 [10974628.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1523-32 [11410486.001]
  • [Cites] Semin Oncol. 2002 Oct;29(5 Suppl 14):18-30 [12422310.001]
  • [Cites] Cancer Res. 2003 Feb 1;63(3):555-9 [12566295.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):246-54 [12909240.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):341-54 [15864276.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 6:vi20-vi24 [15987992.001]
  • [Cites] Expert Opin Biol Ther. 2005 Aug;5(8):1085-93 [16050785.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8646-54 [16314626.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2659-65 [16763280.001]
  • [Cites] Cancer Biol Ther. 2006 Apr;5(4):340-2 [16808060.001]
  • [Cites] J Dent Res. 2007 Feb;86(2):104-14 [17251508.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2191-7 [17538164.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007;69(2 Suppl):S112-4 [17848275.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1626-34 [18316791.001]
  • [Cites] J Natl Cancer Inst. 2008 Mar 19;100(6):407-20 [18334711.001]
  • [Cites] N Engl J Med. 2008 Sep 11;359(11):1116-27 [18784101.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):502-12 [7844612.001]
  • (PMID = 20567625.001).
  • [ISSN] 1718-7729
  • [Journal-full-title] Current oncology (Toronto, Ont.)
  • [ISO-abbreviation] Curr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2880902
  • [Keywords] NOTNLM ; Head-and-neck cancer / egfr inhibitors / epidermal growth factor receptor / overall survival / progression-free survival / tumour response rate
  •  go-up   go-down


34. Bast F, Risteska K, Jovanovic S, Sedlmaier B: [The topical application of mitomycin C in the treatment of scar formation and stenosis in hollow organs of the head and neck: a field report]. Laryngorhinootologie; 2009 Aug;88(8):528-33
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The topical application of mitomycin C in the treatment of scar formation and stenosis in hollow organs of the head and neck: a field report].
  • Besides its use as an adjunction in the treatment of breast, lung and prostate cancer, or as a second-line cytostatic drug for head and neck squamous cell carcinoma (HNSCC), since 1963, MMC has also been successfully used in the suppression of post-operative scar formation, particularly in the field of ophthalmology.
  • In this résumé, we wish to recapitulate our long years of experience in the topical application of Mitomycin C in the treatment of scar formation and stenosis in head and neck organs.
  • The fields of application included laryngeal, tracheal, oesophageal stenosis and stenosis of the external ear canal and the choane.
  • RESULTS: After combined application of MMC and surgical intervention in cases of recurrent stenosising processes in head and neck organs, especially the larynx and the trachea, a sustained improvement was achieved in the pre-operative stenosis level as well as in the pre-operative, severely limited, forced inspiratory volume in 1 second (F1V1).
  • CONCLUSION: The topical application of MMC appears to be an effective adjunction as a concept of treatment for stenosising, scar-forming lesions.
  • This topical application, however, is not a substitute for correct diagnosis and appropriate surgical treatment.
  • [MeSH-major] Airway Obstruction / drug therapy. Antibiotics, Antineoplastic / administration & dosage. Cicatrix / drug therapy. Mitomycin / administration & dosage. Postoperative Complications / drug therapy
  • [MeSH-minor] Administration, Topical. Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Inspiratory Capacity / drug effects. Laryngoscopy. Laryngostenosis / diagnosis. Laryngostenosis / drug therapy. Laryngostenosis / surgery. Laser Therapy. Male. Middle Aged. Recurrence. Reoperation. Retreatment. Retrospective Studies. Tracheal Stenosis / diagnosis. Tracheal Stenosis / drug therapy. Tracheal Stenosis / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Choking.
  • MedlinePlus Health Information. consumer health - Scars.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart, New York.
  • (PMID = 19554503.001).
  • [ISSN] 1438-8685
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


35. Isik M, Dikbas O, Ozcakar L, Isik B, Altundag K: Dermatitis artefacta in a patient with recurrent larynx cancer: a rare self-inflicted dermatosis. South Med J; 2004 Oct;97(10):1024-5
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermatitis artefacta in a patient with recurrent larynx cancer: a rare self-inflicted dermatosis.
  • [MeSH-major] Compulsive Personality Disorder / drug therapy. Life Style. Skin Diseases / etiology
  • [MeSH-minor] Anti-Anxiety Agents / therapeutic use. Carcinoma, Squamous Cell / surgery. Humans. Laryngeal Neoplasms / surgery. Male. Middle Aged. Neoplasm Recurrence, Local / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15558942.001).
  • [ISSN] 0038-4348
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Anxiety Agents
  •  go-up   go-down






Advertisement